









市场行情
/
股票
/
nasdaq-imcr
/

Immunocore Holdings PLC

IMCR

36.130USD

-0.440-1.20%

收盘 12/26, 16:00（美东）报价延迟15分钟

1.80B总市值

亏损市盈率 TTM



Immunocore Holdings PLC

36.130

-0.440-1.20%

概览公司财务分析

概览

公司

财务

分析

关于 Immunocore Holdings PLC 公司

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

Immunocore Holdings PLC简介



公司代码IMCR

公司名称Immunocore Holdings PLC

上市日期Feb 05, 2021

CEOJallal (Bahija)

员工数量493

证券类型Depository Receipt

年结日Feb 05

公司地址92 Park Drive Milton Park

城市ABINGDON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United Kingdom

邮编OX14 4RY

电话441235438600

网址https://www.immunocore.com/

公司代码IMCR

上市日期Feb 05, 2021

CEOJallal (Bahija)

Immunocore Holdings PLC公司高管



名称

名称/职务

职务

持股

持股变动

Prof. John Bell

Independent Chairman of the Board

13.45K

Mr. Roy S. Herbst, M.D., Ph.D.

Non-Executive Independent Director

Mr. Clayton Robertson

Head of Investor Relations

Dr. Bahija Jallal, Ph.D.

Chief Executive Officer, Executive Director

Dr. William Pao, M.D., Ph.D.

Non-Executive Independent Director

Mr. Siddharth Kaul

Non-Executive Independent Director

Ms. Kristine Peterson

Non-Executive Independent Director

Prof. Peter Ratcliffe

Non-Executive Independent Director

Dr. David Berman, M.D., Ph.D.

Head of Research and Development

Mr. Travis Coy

Chief Financial Officer and Head of Corporate Development

名称

名称/职务

职务

持股

持股变动

Prof. John Bell

Independent Chairman of the Board

13.45K

Mr. Roy S. Herbst, M.D., Ph.D.

Non-Executive Independent Director

Mr. Clayton Robertson

Head of Investor Relations

Dr. Bahija Jallal, Ph.D.

Chief Executive Officer, Executive Director

Dr. William Pao, M.D., Ph.D.

Non-Executive Independent Director

Mr. Siddharth Kaul

Non-Executive Independent Director

收入明细

单位: USD更新时间: 10月6日周一

FY2024

FY2023

FY2023Q3

FY2023Q2

FY2022

FY2022Q3

FY2022Q2

FY2020

FY2019

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

226.69M

73.08%

Europe

73.22M

23.61%

International

10.08M

3.25%

Collaboration revenue

213.00K

0.07%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

T. Rowe Price Investment Management, Inc.

14.19%

RTW Investments L.P.

9.78%

Wellington Management Company, LLP

9.60%

Fidelity Management & Research Company LLC

8.81%

PRIMECAP Management Company

7.54%

其他

50.08%

持股股东

占比

T. Rowe Price Investment Management, Inc.

14.19%

RTW Investments L.P.

9.78%

Wellington Management Company, LLP

9.60%

Fidelity Management & Research Company LLC

8.81%

PRIMECAP Management Company

7.54%

其他

50.08%

股东类型

持股股东

占比

Investment Advisor

43.18%

Hedge Fund

28.59%

Investment Advisor/Hedge Fund

24.53%

Venture Capital

1.71%

Research Firm

1.62%

Private Equity

0.77%

Pension Fund

0.56%

Bank and Trust

0.07%

Family Office

0.05%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

300

49.40M

99.22%

-6.80M

2025Q2

293

49.19M

99.31%

-10.02M

2025Q1

304

50.82M

102.67%

-9.36M

2024Q4

304

48.99M

99.30%

-7.33M

2024Q3

299

49.26M

99.94%

-5.38M

2024Q2

298

47.15M

96.58%

+1.62M

2024Q1

283

47.77M

97.93%

+3.51M

2023Q4

262

40.76M

86.07%

-2.70M

2023Q3

246

44.95M

95.97%

-1.86M

2023Q2

236

43.68M

94.12%

-435.38K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

T. Rowe Price Investment Management, Inc.

7.07M

14.03%

+15.84K

+0.22%

Jun 30, 2025

RTW Investments L.P.

4.87M

9.66%

Jun 30, 2025

Wellington Management Company, LLP

5.13M

10.19%

+919.32K

+21.82%

Jul 31, 2025

Fidelity Management & Research Company LLC

4.82M

9.57%

+15.08K

+0.31%

Jun 30, 2025

PRIMECAP Management Company

3.77M

7.49%

+1.09M

+40.80%

Jun 30, 2025

Bellevue Asset Management AG

2.44M

4.85%

+1.22M

+99.86%

Jun 30, 2025

Tang Capital Management, LLC

2.11M

4.18%

+189.90K

+9.91%

Jun 30, 2025

Baker Bros. Advisors LP

2.32M

4.61%

Jun 30, 2025

Deep Track Capital LP

1.80M

3.57%

+388.60K

+27.53%

Jun 30, 2025

BVF Partners L.P.

1.02M

2.03%

+1.02M

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Virtus LifeSci Biotech Products ETF

1.49%

Tema Oncology ETF

1.11%

ALPS Medical Breakthroughs ETF

0.7%

ProShares Ultra Nasdaq Biotechnology

0.19%

SPDR S&P International Small Cap ETF

0.17%

Invesco Nasdaq Biotechnology ETF

0.13%

iShares Intl Small Cap Equity Factor ETF

0.12%

iShares Biotechnology ETF

0.1%

SPDR Portfolio Developed World ex-US ETF

0.01%

Fidelity Nasdaq Composite Index ETF

0.01%

Virtus LifeSci Biotech Products ETF

占比1.49%

Tema Oncology ETF

占比1.11%

ALPS Medical Breakthroughs ETF

占比0.7%

ProShares Ultra Nasdaq Biotechnology

占比0.19%

SPDR S&P International Small Cap ETF

占比0.17%

Invesco Nasdaq Biotechnology ETF

占比0.13%

iShares Intl Small Cap Equity Factor ETF

占比0.12%

iShares Biotechnology ETF

占比0.1%

SPDR Portfolio Developed World ex-US ETF

占比0.01%

Fidelity Nasdaq Composite Index ETF

占比0.01%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Immunocore Holdings PLC的前五大股东是谁？



Immunocore Holdings PLC 的前五大股东如下：
T. Rowe Price Investment Management, Inc.持有股份：7.07M，占总股份比例：14.03%。
RTW Investments L.P.持有股份：4.87M，占总股份比例：9.66%。
Wellington Management Company, LLP持有股份：5.13M，占总股份比例：10.19%。
Fidelity Management & Research Company LLC持有股份：4.82M，占总股份比例：9.57%。
PRIMECAP Management Company持有股份：3.77M，占总股份比例：7.49%。